ArticleThe American journal of gastroenterology2008
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.
Article in The American journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.Trials · 2014Trial
- No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.Journal of affective disorders · 2011Trial
- Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.The American journal of gastroenterology · 2010Trial
- Article
- Psychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medications.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.International journal of psychiatry in medicine · 2018Article
- Interferon-α induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study.Psychological medicine · 2018Article
- Recurrence of depressive disorders after interferon-induced depression.Translational psychiatry · 2017Article
- Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients.Metabolic brain disease · 2016Article
- Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.Scientific reports · 2016Article
- Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.International journal of clinical pharmacy · 2015Article
- Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.World journal of gastroenterology · 2015Review
- A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C.Depression research and treatment · 2014Article
- Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.Journal of psychosomatic research · 2013Article
- HCV-related nervous system disorders.Clinical & developmental immunology · 2012Review
- Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Neuropsychiatric disease and treatment · 2011Article
- The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.Journal of biomedicine & biotechnology · 2011Review
- Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C.The open infectious diseases journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveDepression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin.
methodsIn total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these, 74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72.
resultsThe incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively. Although 22% of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009). Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51).
conclusionDepression during peginterferon and ribavirin therapy was associated with a lower antiviral response. The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.